KRAS and neoplasm: This, coupled with the demonstration that treatment of mice bearing mutant KRAS pancreatic PDXs with KRB-456 inhibits P-MEK and P-AKT and induces apoptosis at doses that are tolerable, suggests that KRB-456 inhibits tumor growth at least in part by inhibiting KRAS oncogenic signaling.